• Explore /
  • Poster
  • / Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.

Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.

Abstract Poster

Authors

null

Lotte Marieke Knapen

Department of Clinical Pharmacy and Toxicology, Care And Public Health Research Institute, Maastricht University Medical Center+ and Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Maastricht, N

Lotte Marieke Knapen , Rutger H.T. Koornstra , Johanna H.M. Driessen , Bas Van Vlijmen , Sander Croes , Stein J. Schalkwijk , Angela Colbers , Winald Gerritsen , David Burger , Frank de Vries , Nielka P. Van Erp

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9540)

DOI

10.1200/JCO.2017.35.15_suppl.9540

Abstract #

9540

Poster Bd #

148

Abstract Disclosures

Similar Posters

First Author: Sigrun Hallmeyer

First Author: Caroline Robert

First Author: Reinhard Dummer

First Author: Natalie Jackson